177 related articles for article (PubMed ID: 37280526)
41. Oligomerization of the mitochondrial protein VDAC1: from structure to function and cancer therapy.
Shoshan-Barmatz V; Mizrachi D; Keinan N
Prog Mol Biol Transl Sci; 2013; 117():303-34. PubMed ID: 23663973
[TBL] [Abstract][Full Text] [Related]
42. AMPK/PGC-1α and p53 modulate VDAC1 expression mediated by reduced ATP level and metabolic oxidative stress in neuronal cells.
Wang Z; Xu T; Sun Y; Zhang X; Wang X
Acta Biochim Biophys Sin (Shanghai); 2024 Feb; 56(2):162-173. PubMed ID: 38298056
[TBL] [Abstract][Full Text] [Related]
43. Voltage-Dependent Anion Channel 1 As an Emerging Drug Target for Novel Anti-Cancer Therapeutics.
Shoshan-Barmatz V; Krelin Y; Shteinfer-Kuzmine A; Arif T
Front Oncol; 2017; 7():154. PubMed ID: 28824871
[TBL] [Abstract][Full Text] [Related]
44. The BH4 domain of anti-apoptotic Bcl-XL, but not that of the related Bcl-2, limits the voltage-dependent anion channel 1 (VDAC1)-mediated transfer of pro-apoptotic Ca2+ signals to mitochondria.
Monaco G; Decrock E; Arbel N; van Vliet AR; La Rovere RM; De Smedt H; Parys JB; Agostinis P; Leybaert L; Shoshan-Barmatz V; Bultynck G
J Biol Chem; 2015 Apr; 290(14):9150-61. PubMed ID: 25681439
[TBL] [Abstract][Full Text] [Related]
45. Voltage-dependent anion channel 1 (VDAC1) overexpression alleviates cardiac fibroblast activation in cardiac fibrosis via regulating fatty acid metabolism.
Tian G; Zhou J; Quan Y; Kong Q; Li J; Xin Y; Wu W; Tang X; Liu X
Redox Biol; 2023 Nov; 67():102907. PubMed ID: 37797372
[TBL] [Abstract][Full Text] [Related]
46. VDAC1-based peptides: novel pro-apoptotic agents and potential therapeutics for B-cell chronic lymphocytic leukemia.
Prezma T; Shteinfer A; Admoni L; Raviv Z; Sela I; Levi I; Shoshan-Barmatz V
Cell Death Dis; 2013 Sep; 4(9):e809. PubMed ID: 24052077
[TBL] [Abstract][Full Text] [Related]
47. Downregulation of voltage-dependent anion channel-1 expression by RNA interference prevents cancer cell growth in vivo.
Koren I; Raviv Z; Shoshan-Barmatz V
Cancer Biol Ther; 2010 Jun; 9(12):1046-52. PubMed ID: 20404552
[TBL] [Abstract][Full Text] [Related]
48. Deletion of VDAC1 Hinders Recovery of Mitochondrial and Renal Functions After Acute Kidney Injury.
Nowak G; Megyesi J; Craigen WJ
Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32290153
[TBL] [Abstract][Full Text] [Related]
49. Vdac1 Downregulation Causes Mitochondrial Disintegration Leading to Hippocampal Neurodegeneration in Scopolamine-Induced Amnesic Mice.
Baghel MS; Thakur MK
Mol Neurobiol; 2019 Mar; 56(3):1707-1718. PubMed ID: 29916145
[TBL] [Abstract][Full Text] [Related]
50. VDAC1 is a molecular target in glioblastoma, with its depletion leading to reprogrammed metabolism and reversed oncogenic properties.
Arif T; Krelin Y; Nakdimon I; Benharroch D; Paul A; Dadon-Klein D; Shoshan-Barmatz V
Neuro Oncol; 2017 Jul; 19(7):951-964. PubMed ID: 28339833
[TBL] [Abstract][Full Text] [Related]
51. Voltage-dependent anion channel 1-based peptides interact with Bcl-2 to prevent antiapoptotic activity.
Arbel N; Shoshan-Barmatz V
J Biol Chem; 2010 Feb; 285(9):6053-62. PubMed ID: 20037155
[TBL] [Abstract][Full Text] [Related]
52. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1.
Geisler S; Holmström KM; Skujat D; Fiesel FC; Rothfuss OC; Kahle PJ; Springer W
Nat Cell Biol; 2010 Feb; 12(2):119-31. PubMed ID: 20098416
[TBL] [Abstract][Full Text] [Related]
53. CoQ
Hseu YC; Thiyagarajan V; Ou TT; Yang HL
Arch Toxicol; 2018 Jan; 92(1):301-322. PubMed ID: 28918503
[TBL] [Abstract][Full Text] [Related]
54. Rewiring of Cancer Cell Metabolism by Mitochondrial VDAC1 Depletion Results in Time-Dependent Tumor Reprogramming: Glioblastoma as a Proof of Concept.
Arif T; Stern O; Pittala S; Chalifa-Caspi V; Shoshan-Barmatz V
Cells; 2019 Oct; 8(11):. PubMed ID: 31661894
[TBL] [Abstract][Full Text] [Related]
55. Targeting the Mitochondrial Protein VDAC1 as a Potential Therapeutic Strategy in ALS.
Shteinfer-Kuzmine A; Argueti-Ostrovsky S; Leyton-Jaimes MF; Anand U; Abu-Hamad S; Zalk R; Shoshan-Barmatz V; Israelson A
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077343
[TBL] [Abstract][Full Text] [Related]
56. Selective induction of cancer cell death by VDAC1-based peptides and their potential use in cancer therapy.
Shteinfer-Kuzmine A; Amsalem Z; Arif T; Zooravlov A; Shoshan-Barmatz V
Mol Oncol; 2018 Jun; 12(7):1077-1103. PubMed ID: 29698587
[TBL] [Abstract][Full Text] [Related]
57. An N-terminal nucleotide-binding site in VDAC1: involvement in regulating mitochondrial function.
Yehezkel G; Abu-Hamad S; Shoshan-Barmatz V
J Cell Physiol; 2007 Aug; 212(2):551-61. PubMed ID: 17503466
[TBL] [Abstract][Full Text] [Related]
58. Mitochondrial ATF2 translocation contributes to apoptosis induction and BRAF inhibitor resistance in melanoma through the interaction of Bim with VDAC1.
Gao Z; Shang Q; Liu Z; Deng C; Guo C
Oncotarget; 2015 Nov; 6(34):36338-53. PubMed ID: 26462148
[TBL] [Abstract][Full Text] [Related]
59. MAVS regulates apoptotic cell death by decreasing K48-linked ubiquitination of voltage-dependent anion channel 1.
Guan K; Zheng Z; Song T; He X; Xu C; Zhang Y; Ma S; Wang Y; Xu Q; Cao Y; Li J; Yang X; Ge X; Wei C; Zhong H
Mol Cell Biol; 2013 Aug; 33(16):3137-49. PubMed ID: 23754752
[TBL] [Abstract][Full Text] [Related]
60. Quinocetone induces mitochondrial apoptosis in HepG2 cells through ROS-dependent promotion of VDAC1 oligomerization and suppression of Wnt1/β-catenin signaling pathway.
Yang X; Tang S; Dai C; Li D; Zhang S; Deng S; Zhou Y; Xiao X
Food Chem Toxicol; 2017 Jul; 105():161-176. PubMed ID: 28343033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
